- Home
- Equipment
- usa washington
- therapeutics to collaborate on developing
Show results for
Refine by
Applications
- Solutions for Endometriosis
- Solutions for Severe but Non-Specific Symptoms
- Acute Kidney Injury (AKI) Device for Reduction of Galectin-3 Levels
- Acute Kidney Injury (AKI) Device for Plasmapheresis Therapy
- Acute Kidney Injury (AKI) Device for Patient Selective Apheresis
- Microbiome Therapeutics for Clinical Trials
- Medical solutions for MiniTC and mini-stem system sector
- Software Solutions for Deep Mutational Scanning & Selection
- Software Solutions for COVID-19
Therapeutics To Collaborate On Developing Equipment & Supplies In Usa Washington
56 equipment items found
Manufactured by:Realize Therapeutics Corp. based inLake Bluff, ILLINOIS (USA)
SIBO is a condition related to excess numbers of bacteria in the small intestine, and can be linked to Irritable Bowel Syndrome, Research clearly shows that certain microbes are very effective at treating SIBO and related issues. Realize Therapeutics is developing formulas to address these health ...
Manufactured by:Entero Therapeutics, Inc. based inBoca Raton, FLORIDA (USA)
Capeserod is a selective 5-HT4 receptor partial agonist, which Entero Therapeutics is repurposing and developing for multiple GI conditions. Based on the biological evidence of expression of 5-HT4b receptor subtype in human GI tract, Entero Therapeutics believes that capeserod may directly or indirectly initiate the peristaltic or secretory reflex by releasing neurotransmitters that can decrease ...
Manufactured by:Evox Therapeutics Limited based inOxford, UNITED KINGDOM
Evox’s proprietary protein engineering technology enables loading of protein therapeutics and tissue targeting moieties onto the surfaces of exosomes, which allows targeting and display of therapeutic proteins to an organ of ...
Manufactured by:PharmAbcine Inc. based inYuseong-gu, SOUTH KOREA
PharmAbcine’s fully human antibody library provides the diversity of antibody candidates for target antigens, ensuring highest success rates of developing therapeutic antibodies for various indications. Our unique and diverse antibody repertoires are constructed by recombination of V gene segments and DJ gene segments in human B-cell derived antibody heavy chains, generating more than 100 ...
Manufactured by:ProImmune Ltd. based inOxford, UNITED KINGDOM
A clear solution to a long-standing problem. Detecting and targeting specific MHC-peptide complexes is of material interest for understanding many disease conditions better and for developing novel therapeutic interventions. It has been very challenging to develop antibodies that bind selectively to an MHC-peptide combination over a more general MHC ...
Manufactured by:Neutron Therapeutics, Inc. based inDanvers, MASSACHUSETTS (USA)
Neutron Therapeutics has developed an accelerator-based, in-hospital neutron source to replace the previously required nuclear reactor. This source is composed of a 2.6 MeV electrostatic proton accelerator and a rotating, solid lithium target for generating neutrons. Neutron Therapeutics will provide this neutron source as part of a comprehensive therapeutic treatment suite, that will combine all ...
Manufactured by:Confo Therapeutics based inGhent/Zwijnaarde, BELGIUM
Confo Therapeutics is building a pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying ...
Manufactured by:ASC Therapeutics based inMilpitas, CALIFORNIA (USA)
Genome editing technologies enables permanent modifications to the genome by harnessing the activities of certain enzymes (e.g. nucleases and integrase) and invoking DNA repair mechanisms at specific locations in the genome. As a therapeutic modality, genome editing can correct a defective gene, disrupt a deleterious gene, or target a therapeutic gene to a precise location in the genome for safe ...
Manufactured by:SpliceBio based inBarcelona, SPAIN
SpliceBio specializes in addressing the challenges of gene therapy by leveraging engineered split inteins. Traditional adeno-associated virus (AAV) vectors are limited by size, restricting their ability to package only small genes, thus leaving many monogenic diseases without effective treatment solutions. The company has focused on the innovative application of inteins, a class of proteins that ...
by:Neoclease based inBoston, MASSACHUSETTS (USA)
Neoclease is pioneering the future of precision medicine through advanced technology in synthetic biology and generative AI. By developing synthetic nucleases, the company enhances gene editing processes to achieve unprecedented specificity and efficacy. These enzymes are meticulously crafted using proprietary algorithms powered by state-of-the-art GPT neural networks, which are ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
Accessing a new repertoire of targets. Two classes of molecule with therapeutic potential that are not currently addressed by antibody drugs are G-protein-coupled receptors and ion channels, largely because they display small epitopes not accessible to traditional antibodies and their sequence is often conserved and thus less likely to be ...
by:Sword Diagnostics, Inc. based inCarmel, INDIANA (USA)
Utilizing our proprietary Sword Swift™ Method Development Process and Sword Swift™ Detection Reagents, our scientists can develop sensitive quantitative assays to measure the amounts of free or bound drug in preclinical or clinical samples with high accuracy and ...
by:DxDiscovery, Inc. based inReno, NEVADA (USA)
Production of monoclonal antibodies (mAbs) is central to all efforts at DxDiscovery. MAb production begins with immunization of a mouse with an antigen. Several weeks after immunization, spleen cells are harvested. B cells in the spleen produce antibody but cannot grow in culture. The spleen cells are fused with cells of a myeloma line. The myeloma cells cannot produce antibody, but they will ...
Manufactured by:Jointechlabs Inc. based inNorth Barrington, ILLINOIS (USA)
Based on our platform and technology, Jointechlabs is developing therapies for unmet medical needs. Our first therapeutic in clinical development JTL-T-01 is a proprietary injectable stem cell scaffold as a biologic therapy for osteoarthritis, for approval under the FDA’s fast-track program. ...
by:Sword Diagnostics, Inc. based inCarmel, INDIANA (USA)
Sword scientists specialize in the development of qualitative or quantitative bioanalytical methods that measure cellular biomolecules active in a specific disease state. Cell-based assays are bioanalytical methods that measure the presence, amount, or activity of biomolecules in cells, cell fractions, nuclear extracts, tissue extracts, or cell extracts. In pharmaceutical drug discovery and ...
Manufactured by:Xenobiotic Detection Systems International, Inc. based inDurham, NORTH CAROLINA (USA)
The Ah receptor (AhR) is a ligand-activated transcription factor that mediates the induction or inhibition of expression of a diverse spectrum of genes resulting in a ligand-specific spectrum of biological and/or toxicological effects. The AhR also has been shown to play a key regulatory role in endogenous physiological responses as well as human disease and it has become an important new target ...
by:Caribou Biosciences, Inc. based inBerkeley, CALIFORNIA (USA)
Natural killer (NK) cells, as their name implies, play an important role in ridding the body of cancer and viruses. NK cells are emerging as an increasingly important cell type for therapeutic development. Solid tumors are particularly challenging to treat and CAR-T cells have largely underperformed in the solid tumor setting. NK cells, however, inherently target both primary solid tumors and ...
by:Sutro Biopharma Inc. based inSouth San Francisco, CALIFORNIA (USA)
Conventional methods for expressing proteins utilize cell lines originating from bacteria, yeast, insects, plants, or mammals. Because these methods require intact, functioning cells, the biochemical and biophysical parameters under which proteins are produced using these methods are inherently limited, often failing to produce many proteins and biologics. Using cell-based expression systems to ...
Manufactured by:Catalent, Inc based inSomerset, NEW JERSEY (USA)
GPEx cell line development technology is a proven technology that generates high-performance, highly stable, production cell lines. Virtually any cDNA (mAb and multigenic applications) can be inserted into cells. To date, over 600 different mAb and mAb fusions and over 160+ different recombinant proteins have been produced using the GPEx system, with 160+ clinical trials utilizing therapeutic ...
by:AbCellera Biologics Inc. based inVancouver, BRITISH COLUMBIA (CANADA)
We search, decode, and analyze natural immune systems to find antibodies that our partners can develop into drugs that improve ...